The administration of an LRRK2 kinase inhibitor can serve as a feasible therapeutic strategy for PD with high LRRK2 kinase activity as it can mitigate oxidative stress or the toxic effects of LRRK2 mutants (Figure 7). This evidence concerns the gene LRRK2 and Parkinson disease.